ProPhase Labs, Inc. is a biotechnology and medical diagnostics company based in Garden City, NY, focusing on consumer health products and diagnostics with a market cap of around $67.2 million.

# Company Summary: ProPhase Labs, Inc.

**Overview:**
ProPhase Labs, Inc. is a biotechnology and medical diagnostics company headquartered in Garden City, New York. The company is publicly traded on the Nasdaq Capital Market under the ticker symbol **PRPH**. It focuses on developing, manufacturing, and marketing health-related products and solutions across various sectors, including consumer health and diagnostics.

**Core Activities:**
- Production and sale of consumer health products, notably Cold-EEZE, a cold remedy brand sold in 2017 for $50 million.
- Development and commercialization of diagnostic testing services and related products.
- Licensing, collaboration, and acquisition activities to expand healthcare offerings.

**Products and Services:**
- Over-the-counter health products, including the Cold-EEZE brand.
- Diagnostics and laboratory testing services.
- Proprietary and licensed health and wellness products, including potential biotechnology applications.
  
**Customer Base:**
- The company serves retail consumers and healthcare providers. Specific numbers of customers and clients are not provided in the filing.

**Employees and Operations:**
- The filing does not specify the total number of employees or detailed operational scale.

**Financials:**
- **Market Capitalization:** Approximately $67.2 million as of June 30, 2024.
- **Outstanding Shares:** 41,879,017 as of March 28, 2025.
- **Revenue, Net Income, and Other Financial Metrics:** Not explicitly disclosed in the provided excerpt. The document focuses primarily on governance, executive compensation, and corporate structure.

**Other Details:**
- The company has made strategic organizational changes, including the sale of its Cold-EEZE brand and ongoing efforts in diagnostics.
- The company’s management includes experienced executives with backgrounds in pharmaceuticals, healthcare, and technology.
- The company emphasizes executive compensation aligned with long-term performance, with certain executives deferring salary to support liquidity.

**Summary:**
ProPhase Labs, Inc. operates within the health and diagnostics industries, focusing on consumer health products, diagnostics services, and potential biotech applications. It has a publicly traded status with a market value of over $67 million, but specific operational metrics like total revenue, net income, and customer count are not provided in the summarized filings.

ProPhase Labs, Inc. is a diversified healthcare company specializing in biotechnology, diagnostics, and over-the-counter pharmaceuticals with a focus on innovative health solutions such as the Cold-EEZE product line.

# ProPhase Labs, Inc. - Company Overview

**Business Description:**

ProPhase Labs, Inc. is a diversified healthcare company engaged in various sectors including biotechnology, diagnostics, and over-the-counter pharmaceuticals. The company is recognized for its innovative approach to health solutions, particularly through its flagship product line, Cold-EEZE, which is a cold remedy that includes lozenges and other formulations designed to reduce the duration and severity of cold symptoms.

## Key Operations:

1. **Biotechnology and Diagnostics:**
   - ProPhase Labs operates ProPhase Diagnostics, a clinical laboratory that provides various testing services. This includes COVID-19 testing and other diagnostic services to assist healthcare providers and patients.
   - They leverage advanced technologies and scientific approaches for accurate and prompt diagnostic testing.

2. **Pharmaceuticals:**
   - The company markets and sells Cold-EEZE products, focusing on consumer healthcare. The product has been positioned as a leading over-the-counter solution for cold symptoms.
   - ProPhase engages in the development and commercialization of additional pharmaceutical products and dietary supplements.

## Key Metrics:

- **Customers:**
  - As of the latest data, ProPhase Labs maintains a vast consumer base primarily in the United States. 
  - The specifics about the total number of customers are not disclosed, but the widespread accessibility of their products suggests a significant market reach.

- **Employees:**
  - The company employs a diverse workforce focused on driving innovation and operational excellence. The exact number of employees is not detailed, but the executive team includes key roles such as CEO, COO, and other executive officers.

- **Revenue:**
  - ProPhase Labs reported revenue of approximately **$278,580** for the fiscal year ending December 31, 2023. 
  - The revenue can be attributed to both the pharmaceutical sales, primarily through Cold-EEZE, and diagnostic testing services.

- **Income:**
  - For the fiscal year ending December 31, 2023, the company reported a **net loss of $16,782,000**.
  - This loss reflects the company's continued investment in growth initiatives, R&D, and operational expansions in the biotech and diagnostic sectors.

## Market Position & Future Goals:

- ProPhase Labs is strategically positioned in the fast-evolving health and wellness sector, with ongoing efforts to expand its diagnostic capabilities and product offerings.
- The company aims to leverage its R&D capabilities to innovate new health solutions, thereby enhancing its product portfolio and market share.

Through a combination of solid product offerings and a diversified business model, ProPhase Labs aims to establish itself as a leading player in the healthcare industry, focusing on improving public health and meeting consumer needs.

ProPhase Labs, Inc.

10-K / April 30, 2025

10-K / April 29, 2024

10-K / April 30, 2025

Company Summary: ProPhase Labs, Inc.